FDA fast-tracks psychedelic drug research following Trump executive order
The Food and Drug Administration announced on Friday a series of actions intended to accelerate the use of psychedelic treatments for serious mental illness, including fast-tracking research for approval to bring new drugs to market.  The move from the FDA comes just six days after President Donald Trump signed an executive order on Saturday directing […]
Original Source
Read the full article at Washingtonexaminer →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.